key: cord-0697895-a61v2615
authors: Pourani, Mohammad Reza; Nekooghadam, Sayyed Mojtaba; Youssefian, Leila; Vahidnezhad, Hassan; Abdollahimajd, Fahimeh
title: CD147 inhibitors as a treatment for melanoma: promising agents against SARS‐CoV‐2 infection
date: 2020-10-24
journal: Dermatol Ther
DOI: 10.1111/dth.14449
sha: 4fb42f518438b3d0666213a9641c60c7458fee19
doc_id: 697895
cord_uid: a61v2615

nan

FA, MRP and SMN contributed to the conception of the work. MRP drafted the manuscript. FA, HV and LY critically revised the manuscript. All authors gave final approval and agreed to be accountable for all aspects of the work ensuring integrity and accuracy scientists have conducted many research projects to discover optimal treatment options. 1 The CD147 protein (known as basigin) is a transmembrane protein that has recently been suggested as a potential receptor for SARS-CoV-2. This protein interacts with several extracellular and intracellular proteins like cyclophilins A and B and matrix metallopeptidases (MMPs). 2 Recent studies have reported that the spike protein of SARS-CoV-2 attaches to host cells via angiotensin-converting enzyme-2 (ACE-2) and CD147 receptors. CD147 is expressed in different tissues such as epithelia, as well as lymphoid and myeloid cells. Notably, CD147 plays an essential role in the pathogenesis of several diseases including certain infectious/inflammatory conditions and cancers. 3 In fact, recent studies have suggested CD147 as a novel tumor marker in the early diagnosis of some cancers like head and neck squamous cell carcinoma and hepatocellular carcinoma. 4 In melanoma, CD147 overexpression fulfills important roles in the proliferation, metastasis, invasiveness, and angiogenesis of malignant melanoma cells. It has been shown that melanoma cell proliferation, migration, and metastasis This article is protected by copyright. All rights reserved. decrease secondary to CD147 silencing via the regulation of MMP-2, MMP-9, and vascular endothelial growth factor. 5 Hatanaka et al. used a combination therapy of EGFR and CD147 inhibitors to treat BRAF-mutated malignant melanoma. 6 shielding of the SARS-CoV-2 spike protein that binds to the CD147 and ACE2 receptors. 8 In conclusion, considering the possible role of CD147 in the pathogenesis of COVID-19, CD147 inhibitors may be considered as promising treatments for SARS-CoV-2 infection.

However, the risks/benefits of anti-CD147 agents as a COVID-19 treatment option should be appraised. High-quality studies concerning this therapeutic target are warranted.

Treatment options for COVID-19: The reality and challenges

Statins: Could an old friend help the fight against COVID-19?

CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement

Targeting CD147 is a novel strategy for antitumor therapy

CD147 Is a Novel Chemotherapy or Prevention Target in

CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation

Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression

FDA approved drugs with pharmacotherapeutic potential for SARS CoV-2 (COVID-19) therapy

A Proposed Randomized, Double Blind

Controlled Study Evaluating Doxycycline for the Prevention of COVID-19 Infection and Disease In Healthcare Workers with Ongoing High Risk Exposure to COVID-19. medRxiv

The authors declare no conflict of interest Data availability statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study This article is protected by copyright. All rights reserved.